Globus Medical (GMED) EBITDA Margin (2011 - 2026)

Globus Medical has reported EBITDA Margin for 16 years, with the latest figure at 16.23% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin rose 283.0% year-over-year to 16.23%; the trailing twelve-month figure through Mar 2026 stood at 19.46% (up 1171.0% YoY), and the FY2025 full-year result was 19.06%, up 1484.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 16.23%, down from 17.55% in the prior quarter.
• The five-year high for EBITDA Margin was 28.88% in Q2 2025, with the low at 1.31% in Q1 2024.
• Historically, EBITDA Margin has averaged 12.86% across 5 years, with a median of 15.56% in 2025.
• Annual changes were most pronounced in 2024 — EBITDA Margin sank 2095 bps — and 2025, when it surged 2396 bps.
• Globus Medical's EBITDA Margin stood at 21.01% in 2022, then sank by 82 bps to 3.82% in 2023, then advanced by 6 bps to 4.05% in 2024, then jumped by 333 bps to 17.55% in 2025, then slipped by 7 bps to 16.23% in 2026.
• The last three EBITDA Margin figures came in at 16.23% (Q1 2026), 17.55% (Q4 2025), and 15.56% (Q3 2025), per Business Quant data.